Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Mesothelioma, Malignant 13Retinoblastoma 9Mesothelioma 9Solid Tumor 7Sarcoma 6Pancreatic Neoplasms 6Lung Neoplasms 6Unspecified Childhood Solid Tumor, Protocol Specific 5Unspecified Adult Solid Tumor, Protocol Specific 5Solid Tumors 5Carcinoma, Non-Small-Cell Lung 5Ovarian Neoplasms 4Wilms Tumor 3Solid Tumor, Adult 3Neuroblastoma 3Colorectal Neoplasms 3Advanced Solid Tumors 3Advanced Solid Tumor 3Thymoma 2Stomach Neoplasms 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Osteosarcoma 2Neoplasms 2Neoplasm Metastasis 2Kidney Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Breast Neoplasms 2

Interventions

fludarabine phosphate 1fludarabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelin-positive Advanced Refractory Solid Tumors × Cyclophosphamide × Other solid neoplasm × Clear all
NCT05531708 2023-03-01

Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors

Shanghai Pudong Hospital

Phase 1 Withdrawn
Other solid neoplasm

Mesothelin-positive Advanced Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡